GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Total Equity: ₹22,674 Mil (As of Mar. 2026)


NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
72 GF Score
Price ₹2,464.70
GF Value ₹2,617.84
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Total Equity?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO +4.07% 72 Total Equity is ₹22,674 Mil as of Mar. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 72/100 and a GF Value™ of ₹2,617.84 (Fairly Valued). The stock has 1 warning sign investors should review.

GlaxoSmithKline Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was ₹22,674 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

GlaxoSmithKline Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Total Equity Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26,629.56 17,412.73 17,776.40 19,513.11 22,674.13

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19,513.11 0.00 17,077.00 0.00 22,674.13
NSE:GLAXO
72GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

GlaxoSmithKline Pharmaceuticals's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=43238.664-20564.532
=22,674

GlaxoSmithKline Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=43238.664-20564.532
=22,674

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹22,674 Mil mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Total Equity of ₹22,674 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' Total Equity too high?
GlaxoSmithKline Pharmaceuticals' current Total Equity is ₹22,674 Mil. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Total Equity compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' Total Equity of ₹22,674 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current Total Equity is ₹22,674 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,617.84, compared to a current price of ₹2,464.70 — trading 5.8% below its estimated fair value. The current Total Equity is ₹22,674 Mil. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Total Equity is ₹22,674 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,464.70 is trading 5.8% below its estimated GF Value™ of ₹2,617.84. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • Total Equity: ₹22,674 Mil
  • GF Value™: ₹2,617.84 vs. price of ₹2,464.70 (5.8% below fair value)
  • GF Score™: 72/100 with 1 warning sign

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
72GF Score

Get the complete analysis for NSE:GLAXO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,464.70
Price
₹2,617.84
GF Value